RT @herbloong: @RTHK_HK @CUHKMedicine @ctosociety Also had the opportunity to highlight our @CUHKMedicine @hkumed study that was published….

RT @tuttsakhil: Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multi….

RT @DFCI_BreastOnc: New study now out in @ESMO_Open: Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2….

Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics-based liquid biopsy assay in @ESMO_Open. Mostly early stage RCC, promising non-invasive tool based on 3 cfDNA features integrated into a stacked ensemble ML model.

Impact of age/sex on efficacy/safety of ramucirumab+paclitaxel as S/M vs continuation of 1L CT: subgroup analysis of the ARMANI trial in @ESMO_Open. S/M benefit irrespective of age/sex, older pts less likely to receive other Tx especially in control arm

Development of a risk score based on clinical–pathological features to predict the presence of gBRCA1/2pathogenic variants in ovarian cancer pts in @ESMO_Open. A model based on few variables that may help pre-test counselling and prioritizing testing

RT @MarioBalsaMD: 💥New @ESMO_Open study on EGFR-mut NSCLC → SCLC transformation: poor survival regardless of tx combo (CT, TKI, ICI). But….

RT @DFCI_BreastOnc: Recently published in @ESMO_Open 👉 Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prio….

Correlation between treatments&outcomes of pts with EGFR-mutated NSCLC that transitioned into SCLC: an international retrospective study in @ESMO_Open. Poor outcomes despite treatment, primary EGFR mutation maintained upon transformation.

Hyalinization-based pathologic response (HPR) and immune infiltration following neoadjuvant RT with or without ICIs in localized UPs in @ESMO_Open. Retrospective cohort, higher rate of hyalinization with ICIs+RT, HPR associated with OS and RFS.

Comprehensive genomic profiling by liquid biopsy in refractory mCRC pts who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial in @ESMO_Open. 41.7% had RAS/BRAF-V600 alterations, 55.5% others, 34.3% were ESCAT tier I.

RT @Al3ssandroRusso: Congrats to my friend @ChiaraCATANIA4 for leading this multicenter international study on SCLC transformation in EGFR….

RT @ArndtVogel: Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers.@ESMO_Open..

RT @ArndtVogel: Clinical outcomes of tumor-agnostic targeting of BRAF, TMB-high, and RET.@ESMO_Open .👉BRAF V600E: 6….

The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma in @ESMO_Open. Actionable targets in 46% of STS, specific subgroups with higher prevalence. WGS-informed therapy in 14% of cases.

RT @m0370: 胃癌の次の標的治療としてほぼ確実なFGFR2b、30%でIHC陽性でその半数が既存の標的治療が無かったのはわかるが、逆に残りの半分はCLDN18陽性やCPS高値やdMMRとオーバーラップするのか。胃癌は本当に混沌の時代が続くな…／ESMO OPEN.

Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study in @ESMO_Open. High frequency of biomarkers associated with response to immunotherapy, as well as other potentially targetable biomarkers.

Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma in @ESMO_Open. 30% prevalence of FGFR2b protein expression, 53.9% of them negative for currently actionable biomarkers.

RT @StephenVLiu: Important report @ESMO_Open from @PTarantinoMD - real world outcomes with T-DXd show much shorter rwPFS in pts previously….

RT @tuttsakhil: Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a….